Market Place
Sourcing Support
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets
26 Dec 2023 //
GLOBENEWSWIRE
Atreca cuts head count by 40% for 2nd time in 3 months
15 Nov 2023 //
FIERCE BIOTECH
Atreca Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Atreca Announces Agreement to Terminate Lease
21 Sep 2023 //
GLOBENEWSWIRE
Atreca axes lead drug, 40% of staff in last-ditch pivot to ADCs
11 Aug 2023 //
FIERCE BIOTECH
Atreca holds off development on its only clinical program, cuts headcount by 40%
11 Aug 2023 //
ENDPTS
Atreca Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101
05 Jun 2023 //
GLOBENEWSWIRE
Atreca Reports 1Q 2023 Financial Results and Recent Corporate Developments
10 May 2023 //
GLOBENEWSWIRE
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at 2023 ASCO
26 Apr 2023 //
GLOBENEWSWIRE
Atreca to Participate in Canaccord Genuity Horizons in Oncology Conference
13 Apr 2023 //
GLOBENEWSWIRE
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results
29 Mar 2023 //
GLOBENEWSWIRE
Atreca to Host Fourth Quarter and Year End 2022 Conference Call
23 Mar 2023 //
GLOBENEWSWIRE
Atreca to Participate at Cowen’s 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody
06 Feb 2023 //
GLOBENEWSWIRE
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
09 Jan 2023 //
GLOBENEWSWIRE
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
10 Nov 2022 //
GLOBENEWSWIRE
Atreca Announces Poster Presentations at (SITC) Annual Meeting
05 Oct 2022 //
GLOBENEWSWIRE
Atreca to Present at Upcoming Investor Conferences
09 Sep 2022 //
GLOBENEWSWIRE
Atreca Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
16 Jun 2022 //
GLOBENEWSWIRE
Oncology biotech Atreca culls 25% of staff
03 Jun 2022 //
FIERCEBIOTECH
Atreca Announces Corporate Reorganization to Extend Cash Runway
01 Jun 2022 //
GLOBENEWSWIRE
Atreca to Present at Upcoming Investor Conferences
19 May 2022 //
GLOBENEWSWIRE
Atreca Reports First Quarter 2022 Financial Results
11 May 2022 //
GLOBENEWSWIRE
Atreca Announces Publication in PNAS: about ATRC-101
04 May 2022 //
GLOBENEWSWIRE
Atreca to Present at Upcoming Virtual Investor Conferences
08 Apr 2022 //
GLOBENEWSWIRE
Atreca Announces Expansion of Preclinical Pipeline
05 Apr 2022 //
GLOBENEWSWIRE
Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022
23 Mar 2022 //
GLOBENEWSWIRE
Atreca to Participate in Cowen 42nd Annual Healthcare Conference
04 Mar 2022 //
GLOBENEWSWIRE
Atreca Reports Q4 and FY 2021 Financial Results and ATRC-101 Data Update
03 Mar 2022 //
GLOBENEWSWIRE
Atreca to Report Q4 2021 Results and Host Year-End Conference Call
24 Feb 2022 //
GLOBENEWSWIRE
Atreca to Present Anti-SARS-CoV-2 Ab Discoveries at Keystone Symposia Conference
04 Jan 2022 //
GLOBENEWSWIRE
Atreca Reports Q3 2021 Financial Results and Recent Corporate Developments
02 Nov 2021 //
GLOBENEWSWIRE
Atreca, Gates Research Institute ink pact on malaria antibody
22 Oct 2021 //
FIERCEBIOTECH
Atreca Announces Poster Presentations at the (SITC)
01 Oct 2021 //
GLOBENEWSWIRE
Atreca to Present at Upcoming Virtual Investor Conferences
04 Aug 2021 //
GLOBENEWSWIRE
Atreca Presentation of Initial Clinical Data from Phase 1b Trial of ATRC-101
26 Jul 2021 //
GLOBENEWSWIRE
Atreca Announces Poster Presentation at the Virtual (AACR) Annual Meeting
10 Mar 2021 //
GLOBENEWSWIRE
Xencor & Atreca Enter Strategic Collab to Discover,Develop Novel T Cell Engaging
08 Jul 2020 //
BUSINESSWIRE
Atreca Announces Poster Presentation at the (ASCO) 2020 Virtual Program
13 May 2020 //
GLOBENEWSWIRE
Atreca, BeiGene, and IGM Biosciences Agree to Collaborate on Novel Antibody
29 Apr 2020 //
GLOBENEWSWIRE
Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101
13 Feb 2020 //
GLOBENEWSWIRE
